Sectors & IndustriesHealthcare

Best Healthcare Stocks to Buy Now (2026)

Top healthcare stocks in 2026 ranked by overall Due Diligence Score. See the best healthcare stocks to buy now, according to analyst forecasts for the healthcare sector.

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best healthcare stocks to buy right now are:

Bioventus (NASDAQ:BVS) is the #1 top healthcare stock out of 1076 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Bioventus (NASDAQ:BVS) is: Value: B, Growth: A, Momentum: C, Sentiment: C, Safety: B, Financials: A, and AI: C.

Bioventus (NASDAQ:BVS) has a Due Diligence Score of 47, which is 20 points higher than the healthcare sector average of 27. It passed 15 out of 33 due diligence checks and has strong fundamentals. Bioventus has seen its stock return 1.14% over the past year, overperforming other healthcare stocks by 44 percentage points.

Bioventus has an average 1 year price target of $15.00, an upside of 69.3% from Bioventus's current stock price of $8.86.

Bioventus stock has a consensus Buy recommendation according to Wall Street analysts. Of the 2 analysts covering Bioventus, 0% have issued a Strong Buy rating, 100% have issued a Buy, 0% have issued a Hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Teva Pharmaceutical Industries (NYSE:TEVA) is the #2 top healthcare stock out of 1076 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Teva Pharmaceutical Industries (NYSE:TEVA) is: Value: B, Growth: B, Momentum: B, Sentiment: A, Safety: B, Financials: C, and AI: B.

Teva Pharmaceutical Industries (NYSE:TEVA) has a Due Diligence Score of 21, which is -6 points lower than the healthcare sector average of 27. Although this number is below the industry average, our proven quant model rates TEVA as a "A".It passed 9 out of 38 due diligence checks and has weak fundamentals. Teva Pharmaceutical Industries has seen its stock return 114.86% over the past year, overperforming other healthcare stocks by 158 percentage points.

Teva Pharmaceutical Industries has an average 1 year price target of $37.38, an upside of 18.58% from Teva Pharmaceutical Industries's current stock price of $31.52.

Teva Pharmaceutical Industries stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 8 analysts covering Teva Pharmaceutical Industries, 87.5% have issued a Strong Buy rating, 12.5% have issued a Buy, 0% have issued a Hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Indivior Pharmaceuticals (NASDAQ:INDV) is the #3 top healthcare stock out of 1076 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Indivior Pharmaceuticals (NASDAQ:INDV) is: Value: B, Growth: B, Momentum: C, Sentiment: A, Safety: B, Financials: B, and AI: C.

Indivior Pharmaceuticals (NASDAQ:INDV) has a Due Diligence Score of 40, which is 13 points higher than the healthcare sector average of 27. It passed 13 out of 33 due diligence checks and has average fundamentals. Indivior Pharmaceuticals has seen its stock return 250.21% over the past year, overperforming other healthcare stocks by 293 percentage points.

Indivior Pharmaceuticals has an average 1 year price target of $44.50, an upside of 33.47% from Indivior Pharmaceuticals's current stock price of $33.34.

Indivior Pharmaceuticals stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 2 analysts covering Indivior Pharmaceuticals, 50% have issued a Strong Buy rating, 50% have issued a Buy, 0% have issued a Hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Out of 71 healthcare stocks that have issued dividends in the past year, the 3 healthcare stocks with the highest dividend yields are:

Novabay Pharmaceuticals (NYSEMKT:NBY) has an annual dividend yield of 317.46%, which is 311 percentage points higher than the healthcare sector average of 6.32%.

Novabay Pharmaceuticals's dividend payout ratio of 34% indicates that its high dividend yield is sustainable for the long-term.

Dominari Holdings (NASDAQ:DOMH) has an annual dividend yield of 20.59%, which is 14 percentage points higher than the healthcare sector average of 6.32%.

Dominari Holdings's dividend payout ratio of 8.4% indicates that its high dividend yield is sustainable for the long-term.

Spok Holdings (NASDAQ:SPOK) has an annual dividend yield of 10.2%, which is 4 percentage points higher than the healthcare sector average of 6.32%. Spok Holdings's dividend payout is not stable, having dropped more than 10% one times in the last 10 years. Spok Holdings's dividend has shown consistent growth over the last 10 years.

Spok Holdings's dividend payout ratio of 162.3% indicates that its high dividend yield might not be sustainable for the long-term.

Healthcare stocks were down -0.62% in the last day, and down -1.35% over the last week. Aptevo Therapeutics was the among the top losers in the healthcare sector, dropping -22.79% yesterday.

Aptevo Therapeutics shares are trading lower after the company announced new interim data for mipletamig in combination with venetoclax and azacitidine in newly diagnosed acute myeloid leukemia patients who are either elderly or unfit for intensive chemotherapy.

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued healthcare stocks right now are:

Embecta (NASDAQ:EMBC) is the most undervalued healthcare stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Embecta has a valuation score of 86, which is 69 points higher than the healthcare sector average of 17. It passed 6 out of 7 valuation due diligence checks.

Embecta's stock has dropped -34.89% in the past year. It has overperformed other stocks in the healthcare sector by 8 percentage points.

Ironwood Pharmaceuticals (NASDAQ:IRWD) is the second most undervalued healthcare stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Ironwood Pharmaceuticals has a valuation score of 86, which is 69 points higher than the healthcare sector average of 17. It passed 6 out of 7 valuation due diligence checks.

Ironwood Pharmaceuticals's stock has gained 158.74% in the past year. It has overperformed other stocks in the healthcare sector by 202 percentage points.

Harmony Biosciences Holdings (NASDAQ:HRMY) is the third most undervalued healthcare stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Harmony Biosciences Holdings has a valuation score of 71, which is 54 points higher than the healthcare sector average of 17. It passed 5 out of 7 valuation due diligence checks.

Harmony Biosciences Holdings's stock has dropped -16.53% in the past year. It has overperformed other stocks in the healthcare sector by 27 percentage points.

57.81% of healthcare stocks rated by analysts are a strong buy right now. On average, analysts expect healthcare stocks to rise by 42.74% over the next year.

6.14% of healthcare stocks have a Zen Rating of A (Strong Buy), 12.29% of healthcare stocks are rated B (Buy), 49.16% are rated C (Hold), 24.82% are rated D (Sell), and 7.59% are rated F (Strong Sell).